Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis

Nikolai Loft; Anne Bregnhøj; Simon Fage; Claus Henrik Nielsen; Christian Enevold; Claus Zachariae; Lars Iversen; Lone Skov

doi:10.1111/dth.15106

Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis

Nikolai Loft^*, Anne Bregnhøj, Simon Fage, Claus Henrik Nielsen, Christian Enevold, Claus Zachariae, Lars Iversen, Lone Skov

^*Corresponding author af dette arbejde

Institut for Klinisk Medicin - Hud- og Kønssygdomme

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Abstract

Studies on switch between interleukin (IL)-17 inhibitors are scarce. We assessed the effectiveness of brodalumab in patients with previous treatment failure of IL-17A inhibitor(s). Patients with psoriasis and previous treatment failure of an IL-17A inhibitor were treated with brodalumab at standard dose. Effectiveness was assessed after 12, 26, and 52 weeks of treatment. The primary outcome was the proportion of patients that had achieved an absolute psoriasis area and severity index (PASI)

Originalsprog	Engelsk
Artikelnummer	e15106
Tidsskrift	Dermatologic Therapy
Vol/bind	34
Nummer	6
Antal sider	7
ISSN	1396-0296
DOI	https://doi.org/10.1111/dth.15106
Status	Udgivet - nov. 2021

Adgang til dokumentet

10.1111/dth.15106

Citationsformater

@article{c3fc67527df4439b87e4277c14fbfad7,

title = "Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis",

abstract = "Studies on switch between interleukin (IL)-17 inhibitors are scarce. We assessed the effectiveness of brodalumab in patients with previous treatment failure of IL-17A inhibitor(s). Patients with psoriasis and previous treatment failure of an IL-17A inhibitor were treated with brodalumab at standard dose. Effectiveness was assessed after 12, 26, and 52 weeks of treatment. The primary outcome was the proportion of patients that had achieved an absolute psoriasis area and severity index (PASI)",

keywords = "psoriasis, therapy - systemic, MODERATE, TO-SEVERE PSORIASIS, systemic, MULTICENTER, EFFICACY, SAFETY, therapy, PHASE-3, SECUKINUMAB, SEVERE PLAQUE PSORIASIS, DOUBLE-BLIND, BIMEKIZUMAB",

author = "Nikolai Loft and Anne Bregnh{\o}j and Simon Fage and Nielsen, {Claus Henrik} and Christian Enevold and Claus Zachariae and Lars Iversen and Lone Skov",

note = "{\textcopyright} 2021 Wiley Periodicals LLC.",

year = "2021",

month = nov,

doi = "10.1111/dth.15106",

language = "English",

volume = "34",

journal = "Dermatologic Therapy",

issn = "1396-0296",

publisher = "Wiley-Blackwell Publishing, Inc.",

number = "6",

}

TY - JOUR

T1 - Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis

AU - Loft, Nikolai

AU - Bregnhøj, Anne

AU - Fage, Simon

AU - Nielsen, Claus Henrik

AU - Enevold, Christian

AU - Zachariae, Claus

AU - Iversen, Lars

AU - Skov, Lone

PY - 2021/11

Y1 - 2021/11

N2 - Studies on switch between interleukin (IL)-17 inhibitors are scarce. We assessed the effectiveness of brodalumab in patients with previous treatment failure of IL-17A inhibitor(s). Patients with psoriasis and previous treatment failure of an IL-17A inhibitor were treated with brodalumab at standard dose. Effectiveness was assessed after 12, 26, and 52 weeks of treatment. The primary outcome was the proportion of patients that had achieved an absolute psoriasis area and severity index (PASI)

AB - Studies on switch between interleukin (IL)-17 inhibitors are scarce. We assessed the effectiveness of brodalumab in patients with previous treatment failure of IL-17A inhibitor(s). Patients with psoriasis and previous treatment failure of an IL-17A inhibitor were treated with brodalumab at standard dose. Effectiveness was assessed after 12, 26, and 52 weeks of treatment. The primary outcome was the proportion of patients that had achieved an absolute psoriasis area and severity index (PASI)

KW - psoriasis

KW - therapy - systemic

KW - MODERATE

KW - TO-SEVERE PSORIASIS

KW - systemic

KW - MULTICENTER

KW - EFFICACY

KW - SAFETY

KW - therapy

KW - PHASE-3

KW - SECUKINUMAB

KW - SEVERE PLAQUE PSORIASIS

KW - DOUBLE-BLIND

KW - BIMEKIZUMAB

U2 - 10.1111/dth.15106

DO - 10.1111/dth.15106

M3 - Journal article

C2 - 34418225

SN - 1396-0296

VL - 34

JO - Dermatologic Therapy

JF - Dermatologic Therapy

IS - 6

M1 - e15106

ER -

Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater